Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 4 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar genedom (97.97) Submitted: 9/12/2013 3:07:59 AM : Outperform Start Price: $37.19 ACOR Score: -23.64

Short term momentum

Featured Broker Partners


Advertisement